<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Bill</title>
	<atom:link href="http://www.tapanray.in/tag/bill/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Access To Comprehensive Healthcare Merits Multipronged Approach</title>
		<link>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=access-to-comprehensive-healthcare-merits-multipronged-approach</link>
		<comments>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/#comments</comments>
		<pubDate>Mon, 10 Dec 2018 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[band-aid]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[comprehensive]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Gordian]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[knot]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[multi-pronged]]></category>
		<category><![CDATA[multifactorial]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9296</guid>
		<description><![CDATA[Since the turn of the new millennium, several high profile and flagship health schemes are being announced in India by the Union successive governments. Some of the important ones will include the National Health Mission, Rashtriya Swasthya Bima Yojana (RSBY) - a Health &#8230; <a href="http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/access-to-comprehensive-healthcare-merits-multipronged-approach/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>High Innovation-Cost Makes Cancer Drugs Dear: A Fragile Argument?</title>
		<link>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument</link>
		<comments>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/#comments</comments>
		<pubDate>Mon, 18 Sep 2017 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[17]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[argument]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[bust]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[CM]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[dear]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovation-cost]]></category>
		<category><![CDATA[intensive]]></category>
		<category><![CDATA[jeopardizing]]></category>
		<category><![CDATA[Keytruda]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[policymakers]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technological]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[tribe]]></category>
		<category><![CDATA[unaffordable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8417</guid>
		<description><![CDATA[Cancer is a major cause of high morbidity and mortality in India, just many other countries, according to a report of the World Health Organization (W.H.O). While deaths from cancer worldwide are projected to continue to rise to over 1.31 &#8230; <a href="http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mental Health Problem: A Growing Concern In The Healthcare Space Of India</title>
		<link>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india</link>
		<comments>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/#comments</comments>
		<pubDate>Mon, 16 Jan 2017 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[anxiety]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[dementia]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[Development Goals]]></category>
		<category><![CDATA[disorder]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[illness]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lok]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Rajya]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sabha]]></category>
		<category><![CDATA[SDG]]></category>
		<category><![CDATA[series]]></category>
		<category><![CDATA[stigma]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8049</guid>
		<description><![CDATA[A thud! Something fell from high above! In no time, a bright young life of just a 32-year-old highly accomplished professional &#8211; a widely admired soul, vanished in the thin year, for good, mostly unnoticed in the quiet neighborhood, initially. &#8230; <a href="http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/mental-health-problem-a-growing-concern-in-the-healthcare-space-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Highest Billionaire Wealth Concentration, India Tops Malnutrition Chart in South Asia: &#8220;What Future Do You Want?&#8221;</title>
		<link>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want</link>
		<comments>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/#comments</comments>
		<pubDate>Mon, 26 Jan 2015 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amit]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[Billionaire]]></category>
		<category><![CDATA[BJP]]></category>
		<category><![CDATA[Chart]]></category>
		<category><![CDATA[Concentration]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Davos]]></category>
		<category><![CDATA[demographic]]></category>
		<category><![CDATA[dividend]]></category>
		<category><![CDATA[Gates]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[highest]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequality]]></category>
		<category><![CDATA[Justice Louis Brandeis]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[oxfam]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Shah]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tops]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UNICEF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Wealth]]></category>
		<category><![CDATA[WEF]]></category>
		<category><![CDATA[What Future Do You Want]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6352</guid>
		<description><![CDATA[Two recent global research reports, though on different spheres, place India at the top of the respective blocks. However, the take away messages that the studies offer are indeed poles apart in qualitative terms and worth pondering over collectively. On &#8230; <a href="http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma FDI Debate: Highly Opinionated, Sans Assessment of Tangible Outcomes?</title>
		<link>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes</link>
		<comments>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/#comments</comments>
		<pubDate>Mon, 18 Nov 2013 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[addition]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[asset]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[FIPB]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[ilk]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Opinionated]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shorn]]></category>
		<category><![CDATA[tangible]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[wage]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4217</guid>
		<description><![CDATA[In 2001, the Government of India (GoI) allowed 100 percent Foreign Direct Investments (FDI) in the pharmaceutical sector through automatic route to attract more investments for new asset creation, boost R&#38;D, new job creation and ultimately to help aligning Indian &#8230; <a href="http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-fdi-debate-highly-opinionated-sans-assessment-of-tangible-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Vaccines Development: Is it Just a Business Based on Fear?</title>
		<link>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=vaccines-development-is-it-just-a-business-based-on-fear</link>
		<comments>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/#comments</comments>
		<pubDate>Mon, 26 Aug 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[Buchwald]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[diphtheria]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[enough]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[fear]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[Gates]]></category>
		<category><![CDATA[GAVI]]></category>
		<category><![CDATA[Gerhard]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JV]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pox]]></category>
		<category><![CDATA[prevention]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TB]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[Tuberculosis]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3486</guid>
		<description><![CDATA[‘Vaccination – A Business based on fear’, is the title of a book written by Dr. Gerhard Buchwald M.D, a German medical doctor and a vaccination critic. This book talks about: “The damage and the deaths caused by vaccination are written &#8230; <a href="http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/vaccines-development-is-it-just-a-business-based-on-fear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quick implementation of the undiluted ‘Central Drug Authority (CDA)’ Bill is essential for emerging India</title>
		<link>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india</link>
		<comments>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/#comments</comments>
		<pubDate>Mon, 21 Feb 2011 00:30:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=299</guid>
		<description><![CDATA[Many industry experts after having evaluated the provisions of the original draft proposal for forming a Central Drugs Authority (CDA) in the country, commended and supported this laudable initiative of the Government. This Bill also known as, “The Drugs &#38; &#8230; <a href="http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quick implementation of the UNDILUTED ‘Central Drug Authority (CDA)’ Bill is essential for emerging India</title>
		<link>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2</link>
		<comments>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/#comments</comments>
		<pubDate>Sun, 31 Jan 2010 01:30:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=476</guid>
		<description><![CDATA[Many industry experts after having carefully evaluated the provisions of the original draft of the proposal of forming a CDA in the country commended and supported this praiseworthy initiative of the Government. This Bill also known as, “The Drugs &#38; &#8230; <a href="http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The relevance of the Indian version of the Bayh-Dole Act – the country needs all stakeholders’ open debate on the proposed bill.</title>
		<link>http://www.tapanray.in/the-relevance-of-the-indian-version-of-the-bayh-dole-act-the-country-needs-all-stakeholders-open-debate-on-the-proposed-bill/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-relevance-of-the-indian-version-of-the-bayh-dole-act-the-country-needs-all-stakeholders-open-debate-on-the-proposed-bill</link>
		<comments>http://www.tapanray.in/the-relevance-of-the-indian-version-of-the-bayh-dole-act-the-country-needs-all-stakeholders-open-debate-on-the-proposed-bill/#comments</comments>
		<pubDate>Mon, 19 Oct 2009 01:30:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[academia]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[Bayh]]></category>
		<category><![CDATA[Bayh-Dole]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[Dole]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[proposed]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[version]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=751</guid>
		<description><![CDATA[The Bayh-Dole Act is an American legislation, which was originally sponsored by two US senators named Birch Bayh and Bob Dole. This Act deals with Intellectual Property (IP) arising out of US government funding. Bayh-Dole Act is also known as &#8230; <a href="http://www.tapanray.in/the-relevance-of-the-indian-version-of-the-bayh-dole-act-the-country-needs-all-stakeholders-open-debate-on-the-proposed-bill/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-relevance-of-the-indian-version-of-the-bayh-dole-act-the-country-needs-all-stakeholders-open-debate-on-the-proposed-bill/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Professor, Counterfeit Drugs, CDA Bill and the New Health Minister</title>
		<link>http://www.tapanray.in/the-professor-counterfeit-drugs-cda-bill-and-the-new-health-minister/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-professor-counterfeit-drugs-cda-bill-and-the-new-health-minister</link>
		<comments>http://www.tapanray.in/the-professor-counterfeit-drugs-cda-bill-and-the-new-health-minister/#comments</comments>
		<pubDate>Thu, 04 Jun 2009 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[Counterfeit Drugs]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Professor]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=869</guid>
		<description><![CDATA[Just a couple of days ago, I met Professor Sam Gupta, an American professor of Indian origin. Prof. Gupta has specialized in nuclear medicine and hails from a well reputed North American University. Dr. Gupta, like many others, had left &#8230; <a href="http://www.tapanray.in/the-professor-counterfeit-drugs-cda-bill-and-the-new-health-minister/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-professor-counterfeit-drugs-cda-bill-and-the-new-health-minister/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
